PMN ProMIS Neurosciences Inc. Insider Trading

Director Kirwin Patrick D. buys 4,000 shares of PMN at $11.33 on 2026-04-22; position up 612.6% post-transaction. Stock now -61.1% from 52-week high.

Kirwin Patrick D., a director at ProMIS Neurosciences, purchased 4,000 shares at $11.33 on 2026-04-22, increasing his holding by 612.6% and committing $45,320.00 to the position. This marks his second insider buy in the company's equity; his first open-market purchase at PMN on 2024-08-14 achieved a 90d return of +1861.3%, well-timed on both 30-day (+2361.6%) and 90-day bases. The current share price of $10.88 sits -61.1% below the 52-week high of $28.00 and -37.6% over the trailing 30 days, suggesting the director is purchasing into a sharp recent decline after the stock had risen 15.4% over the prior 90 days. The company reported a full-year net loss of $-11,580,126.00 on a $97,568,499.84 market capitalization, indicating unprofitability. This substantial position increase by a director during a downtrend, paired with his prior success timing a buy at this ticker, merits investor attention to the company's near-term fundamentals and the director's forward view.

Director Williams Eugene purchased 2,000 shares of PMN at $24.40 on 2026-03-05, expanding holdings to 12,397 shares.

Williams Eugene, a director of ProMIS Neurosciences, purchased 2,000 shares at $24.40, increasing his stake by 19.2% to 12,397 shares. The transaction occurred after three consecutive open-market buys on 2026-03-02, 2026-03-03, and 2026-03-04—a concentrated buying pattern over four consecutive trading days. The stock now trades at $23.40, down 16.4% from its 52-week high of $28.00 despite a 49.5% gain over the preceding 30 days. Against this backdrop of fundamental headwinds—the company is unprofitable with net income of $-11,580,126.00 and a P/E ratio of 212.73—the director's rapid accumulation suggests a conviction in near-term upside, though prior same-ticker outcomes are not yet measurable.

Director Williams Eugene bought 4,000 PMN shares across 3 trades (Mar 2-4) for $92,420.00 at blended avg $23.10

Williams Eugene, a director of ProMIS Neurosciences, completed 3 separate purchases totaling 4,000 shares for $92,420.00 between March 2 and March 4, 2026, increasing his holdings by 62.5% from 6,397 to 10,397 shares. The transactions occurred at prices ranging from $21.89 to $24.00, within 14.1% of the current $24.05 price, and notably during a period of significant price momentum: the stock has risen 71.2% over 30 days and 215.2% over 90 days from a 52-week low of $6.76. The timing occurs in a company context marked by net losses of $-11,580,126.00 and an elevated P/E of 218.64, creating a backdrop where insider accumulation suggests conviction independent of traditional valuation metrics. The substantial share increase during strong upward momentum warrants examination of the underlying strategic or operational drivers supporting this accumulation.

CDO Kaplan buys 1,629 shares of PMN at $15.35; holdings rise to 3,941 shares (+70.5%)

Chief Development Officer Johanne Kaplan purchased 1,629 shares at $15.35 on 2026-02-19, increasing her holdings by 70.5% to 3,941 shares total, representing a $25,005.15 commitment. The transaction occurred when the stock was -43.6% from its 52-week high of $28.00 but +67.4% over the prior 30 days and +99.2% over 90 days, suggesting material recent momentum. The company is operating with a net loss of $-11,580,126.00 and trades at a P/E of 143.55 despite an $849.7M market cap, indicating elevated valuation relative to negative earnings. The substantial buy by a C-suite officer at these valuations and after significant recent gains merits investor attention to understand the company's financial trajectory and insider perspective on near-term prospects.

ABG Management Ltd. (10% owner) acquired 700,741 shares of PMN at $12.13 for $8,499,988.33; holdings surged 289.1% to 943,090 shares

ABG Management Ltd., already a 10% owner, deployed $8,499,988.33 to purchase 700,741 shares at $12.13, dramatically expanding its stake from 242,349 shares to 943,090 shares in a single transaction. The stock has recovered 70.4% over 30 days and 38.3% over 90 days from recent lows, but remains 53.2% below its 52-week high of $28.00, suggesting the purchase occurred in a recovery phase but still well below peak valuation. The company is unprofitable (net income of $-11,580,126.00) and trades at a P/E of 119.09 with a market cap of $704,925,541.00, indicating this is a speculative or turnaround story rather than a mature profitable enterprise. This near-tripling of an anchor shareholder's position in an unprofitable biotech signals substantial conviction in future value creation, though the absence of profitability means investors must carefully evaluate whether the recovery trajectory and pipeline justify the concentrated exposure now being assumed.

Insider Milbury buys 30,392 shares of PMN at $0.49; holdings jump 202.7% to 45,389 shares amid $-10.1M net loss.

Milbury Max A. purchased 30,392 shares at $0.49, increasing his stake from 14,997 shares to 45,389 shares—a 202.7% increase in holdings. The company is currently unprofitable with net income of $-10,117,029.00, and the stock has declined 56.8% from its 52-week high of $31.75, though it has recovered 27.6% over the past 30 days and 35.7% over the past 90 days. The purchase was executed at a substantial discount to the current price of $13.72, suggesting the insider acquired shares when the stock was trading near multi-month lows. This acquisition pattern—a material increase in holdings at depressed price levels—warrants monitoring to assess whether this represents personal reaccumulation or a broader shift in confidence following recent price recovery.

Chief Scientific Officer Neil Cashman buys 15,000 shares of PMN at $0.97; holdings rise to 16,617 shares (+927.6%)

Cashman purchased 15,000 shares at $0.97 on 2025-02-10, increasing his position from 1,617 to 16,617 shares—a 927.6% increase in holdings. The current price is $22.80, reflecting a significant rallying market price relative to his transaction price, though the stock remains -63.4% below its 52-week high of $62.25. The company reports net income of $9,275,825.00, yet also carries negative full-year net income from the most recent fiscal year, indicating inconsistency between the current and historical profitability picture. The substantial expansion of the CSO's equity stake during a period of stock weakness (down 8.8% in 30 days) warrants examination of whether this reflects his conviction in near-term strategy, though the transaction details alone do not resolve whether the company's recent return to profitability signals durable recovery or temporary improvement.

Director Madge K. Shafmaster purchased 200,000 shares across 3 transactions for $255,750.00 at blended average $1.28

Director Madge K. Shafmaster executed 3 separate purchases totaling 200,000 shares for $255,750.00 between September 20-24, 2024, increasing her holdings from 8,333 shares to 208,333 shares (+2400.1% net change). The transaction occurred at prices ranging from $1.25 to $1.30, well below the current market price of $32.50 and near the 52-week low of $24.25, despite the stock trading at -53.7% from its 52-week high. This represents a material capital commitment by a board-level director during a period when the company is unprofitable (full-year net income of $-2,623,657.00). The magnitude of the purchase relative to prior holdings and the director's elevated position warrant examination of whether circumstances have changed materially since the earlier 52-week high.

10% Owner Gordon Michael S buys 93,223 shares at $1.25 avg; stock at $31.00 vs. 52-wk high $70.25

Gordon Michael S, a 10% owner, executed 2 separate purchases totaling 93,223 shares for $116,880.03 at a blended average price of $1.25 on 2024-09-16 and 2024-09-17. The stock currently trades at $31.00, representing a 55.9% decline from its 52-week high of $70.25, and is down 20.0% over the past 90 days. His prior trade at PMN (a buy on 2024-07-31) produced a -4.8% 30-day return, and his cross-ticker track record shows 1 prior buy with an average 30-day return of -4.8%. The company is unprofitable with a full-year net income of -$2,623,657.00. The timing of this accumulation follows a significant drawdown in stock price but occurs within an ongoing downtrend, and prior purchase patterns at this ticker have not yet demonstrated positive outcomes at measurable intervals.

Director Kirwin purchased 10,000 shares of PMN at $1.25; stock down 55.5% from 52-week high despite unprofitable $-2.6M FY.

Director Patrick D. Kirwin purchased 10,000 shares at $1.25 on 2024-08-14, increasing his stake by 18.9% to 62,983 shares post-transaction. The purchase occurred as PMN stock traded down 55.5% from its 52-week high of $70.25 and down 41.8% over the prior 30 days, amid a backdrop of negative full-year net income of $-2.6M. The transaction represents a discrete insider acquisition during a period of significant price weakness and financial underperformance, warranting investor attention to whether this signals management confidence in a recovery or reflects structural challenges at the company.